Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy.

Trial Profile

Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2015

At a glance

  • Drugs Cabazitaxel (Primary) ; Topotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Aug 2015 Results published in the Journal of Thoracic Oncology.
    • 02 Jun 2015 Results of retrospective analysis presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 10 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top